Investor Presentaiton

7 Commercial execution and innovation Diabetes care Use of GLP-1 treatments has increased globally, yet only ~6 million people treated ~6 million people, 3% of diabetes prescriptions, use a GLP-1 with large differences across markets Million people 7 6 5 4 OZEMPİC semaglutide injection RYBELSUSⓇ semaglutide tablets Global: 3% 8% 3 2 1% 1% 3% 1 0 2017 2021 EMEA Region China Rest of World North America GLP-1 share of diabetes prescription EMEA: Europe, Middle East and Africa; Region China covers Mainland China, Taiwan and Hong Kong Source: IQVIA MAT, December 2021 Novo NordiskⓇ CMD22 CAPITAL MARKETS DAY

View entire presentation